Thermal hoods, boxes, cooling elements, data loggers: Ecocool supplies suitable equipment for GDP-compliant transportation of temperature-sensitive pharmaceuticals.
The Covid pandemic and its repercussions have changed the pharmaceutical industry and the healthcare markets. Richard Stedman, the CEO of ACG Engineering, discusses the lessons learned from the global supply chain disruptions and how innovative equipment helps pharma manufacturers overcome the challenges.
Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.
As part of what seems to be a general pattern of staff reductions in the pharmaceutical industry worldwide, a growing number of Western drugmakers are downsizing their sales and marketing presence in India.
Bayer is increasingly shifting the commercial focus of its pharmaceutical business away from Europe and toward the US and China, Stefan Oelrich, head of the German group’s pharmaceuticals arm, said in an interview with Financial Times during the JPMorgan Healthcare conference in San Francisco.
Granules India, a Hyderabad-based pharma company, is partnering compatriot clean energy company Greenko ZeroC to develop green zones for the sustainable manufacture of drugs and their intermediates.
Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.
The CEOs of seven multinational pharmaceutical companies have announced that they are taking joint action to achieve near-term emissions reduction targets and accelerate the delivery of net zero health systems.
Dutch CDMO Symeres has acquired Exemplify Biopharma, a US-based contract research organization (CRO) based in Cranbury, New Jersey, USA. The deal further strengthens Symeres’ foothold in the US, where it already generates about 50% of its revenues.
Swiss distributor DKSH is poised to acquire North American specialty chemicals distributor Terra Firma, expanding the platform of its Performance Materials business unit to the US and Canada.
Interview with Michael Postlethwaite, Senior Director, Sales & Business Development, European Territories, AmbioPharm
Interview with Christophe Couturier and Claudia Berrón, Avantor
Swiss chemical, pharmaceutical and life sciences companies help drive research around the world, and major players have research activities in the US, Singapore, Japan, as well as EU facilities in the United Kingdom and Germany. But do not underestimate the role of the domestic regional clusters and industrial sites.
With the cost pressures and time to market challenges that the health care industry faces, pharmaceutical and biotech companies must figure out ways to increase laboratory efficiency by managing its resources more effectively.
